Kabirullah Lutfy1, Imran Khaliq, F Ivy Carroll, Nigel T Maidment. 1. Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, University of California, Los Angeles, 760 Westwood Plaza, Los Angeles, CA 90024, USA.
Abstract
RATIONALE: Orphanin FQ/nociceptin (OFQ/N), the endogenous ligand of the opioid receptor-like (ORL-1) receptor, shows similarities to dynorphin A (1-17) in structure and functions. Dynorphin and other kappa opioid receptor agonists have been shown to block cocaine sensitization. OBJECTIVE: The present study was designed to examine the ability of OFQ/N to block cocaine-induced behavioral sensitization. METHODS: Rats were habituated to testing chambers for 1 h, injected with artificial cerebrospinal fluid (aCSF) or OFQ/N (15 nmol) followed by saline or cocaine (20 mg/kg) and locomotor activity was measured for a further 1 h. Rats were treated similarly for the next 2 days except the dose of OFQ/N was doubled on each subsequent day. Rats were then challenged with cocaine (7.5 mg/kg) in the absence of OFQ/N on day 8. The specificity of OFQ/N's action was examined in the presence of J-113397 (30 nmol), an ORL-1 receptor antagonist. The ability of OFQ/N to block the context-independent component of cocaine sensitization was also tested wherein rats were treated in their home cages on days 1-3. Finally, the effect of intra-VTA OFQ/N administration on cocaine sensitization was examined. RESULTS: Sensitization did not develop in rats repeatedly treated with OFQ/N, via either route of administration, prior to cocaine administration on days 1-3. The inhibitory effect of OFQ/N was not dependent on context and was blocked by pretreatment with J-113397. CONCLUSION: Our results indicate that OFQ/N blocks cocaine-induced behavioral sensitization through activation of the ORL-1 receptor and that the VTA may be one of the substrates for this action of OFQ/N.
RATIONALE: Orphanin FQ/nociceptin (OFQ/N), the endogenous ligand of the opioid receptor-like (ORL-1) receptor, shows similarities to dynorphin A (1-17) in structure and functions. Dynorphin and other kappa opioid receptor agonists have been shown to block cocaine sensitization. OBJECTIVE: The present study was designed to examine the ability of OFQ/N to block cocaine-induced behavioral sensitization. METHODS:Rats were habituated to testing chambers for 1 h, injected with artificial cerebrospinal fluid (aCSF) or OFQ/N (15 nmol) followed by saline or cocaine (20 mg/kg) and locomotor activity was measured for a further 1 h. Rats were treated similarly for the next 2 days except the dose of OFQ/N was doubled on each subsequent day. Rats were then challenged with cocaine (7.5 mg/kg) in the absence of OFQ/N on day 8. The specificity of OFQ/N's action was examined in the presence of J-113397 (30 nmol), an ORL-1 receptor antagonist. The ability of OFQ/N to block the context-independent component of cocaine sensitization was also tested wherein rats were treated in their home cages on days 1-3. Finally, the effect of intra-VTA OFQ/N administration on cocaine sensitization was examined. RESULTS: Sensitization did not develop in rats repeatedly treated with OFQ/N, via either route of administration, prior to cocaine administration on days 1-3. The inhibitory effect of OFQ/N was not dependent on context and was blocked by pretreatment with J-113397. CONCLUSION: Our results indicate that OFQ/N blocks cocaine-induced behavioral sensitization through activation of the ORL-1 receptor and that the VTA may be one of the substrates for this action of OFQ/N.
Authors: J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat Journal: Nature Date: 1995-10-12 Impact factor: 49.962
Authors: R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli Journal: Science Date: 1995-11-03 Impact factor: 47.728
Authors: Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason Journal: Am J Psychiatry Date: 2019-05-06 Impact factor: 18.112
Authors: Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri Journal: Pharmacol Rev Date: 2016-03-08 Impact factor: 25.468